Zeleciment Biosimilar Fab Fragment (Transferrin Receptor 1) for Research

Cat No.: GMP-Bios-INN-1472

Anti-TFRC/CD71 therapeutic antibody (Pre-made Zeleciment biosimilar,Fab) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Zeleciment (development code DYNE-251) is a humanized Fab fragment targeting transferrin receptor 1 (TFRC). It is developed by Dyne Therapeutics for Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy et al. in Phase III development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1472-1mg 1mg 3090
GMP-Bios-INN-1472-10mg 10mg
GMP-Bios-INN-1472-100mg 100mg
GMP-Bios-INN-1472-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Zeleciment biosimilar, Fab, Anti-TFRC/CD71 Antibody: Anti-CD71/TFRC/Transferrin receptor protein 1/TR therapeutic antibody
INN Name Zeleciment
Target TFRC/CD71
Format Fab
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status Active
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2023
Year Recommended 2024
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech na